Yarob Zeidan’s Post

In 2020, over 900,000 people were diagnosed with Liver Cancer globally. In a recent digital study, we helped AstraZeneca and Charité - Universitätsmedizin Berlin gain insights from patients with Hepatocellular carcinoma (HCC) and the rarer form of Biliary tract cancer (BTC). The objective was to understand more about patients, and their caregivers, and to see what really is happening in the real-world #behindpatienteyes. The results of the survey were also presented at @Deutscher Krebskongress 2024.   We uncovered a significant gap in patient and caregiver involvement in treatment decisions. Key Insights: - 63.8% of patients expressed a desire for their relatives/caregivers to be included in treatment decisions. - Knowledge gaps among patients and caregivers regarding the disease, treatment, and support groups may contribute to this discrepancy.   - 72.5% of respondents (patients & caregivers) rely heavily on internet resources for disease-related information. Implications: The data underscores a pressing need for enhanced patient and caregiver information, education, and involvement in the cancer treatment journey. By bridging these gaps, we can empower patients and caregivers to make informed decisions and improve overall treatment outcomes. In the realm of cancer therapy, the voices of patients and caregivers are indispensable. Yet, too often, these perspectives are sidelined in treatment decisions. Contact DontBePatient Intelligence, or one of our team, to receive a free copy of the poster or learn more about how we could support you. #patientexperience #patientengagement #patientjourney #patientvoice #patientcommunication #patientadvocacy #patientcare #patientcentricity #patientinsights #realworldevidence #realworlddata #emotionaljourney

#livercancer @ DontBePatient Intelligence | Another successful example of when pharma and medical experts work together to gather insights from over 300 #patients (and #caregivers) to better understand the decision-making processes and knowledge levels of patients with #hepatobiliary #cancer. Uncovering the #patientjourney, and the experience of those around them, can enable better approaches to supporting patients to be identified, in line with #realworld #patientexperience & needs and #preferences. It also helps understand and improve the experience for future patients and their caregivers. #behindpatienteyes #livercancer #hcc #btc #patientengagement #patientcare #patientjourney #patientexperience Dr.med habil Gregor Stavrou, FEBS (HPB,SurgOnc), Prof. Dr. Christoph U. Herborn, Dr. Kirsten Dettmar, Dr. Karl Matussek, Dr. Helen Beckmann, Patrick, Dr. Paul Kaschutnig, Dr. Hilke Friccius, Julia, AstraZeneca, Charité - Universitätsmedizin Berlin, Gunnar, Edgar, Prof. Dr. Jochen A. Werner, Oriol, Dr. Andreas Poschenrieder, Dr. Ute Simon, Jens Hennicke, Jens, Francois, Dr. med. Steffen Achenbach, Michael, Michael, Melissa, Christina, Osvaldo, Sarah, Ricardo, Stamen, Patric, Ken, Simone, Gernot, Wolfgang, Judith, Dr. med. Christopher Wenck, Dr. Andra Kuske, Guillaume, Matthias,

Colorectal Cancer: Signs and Symptoms At the intersection of healthcare and innovation, understanding and addressing colorectal cancer is essential to improving outcomes in Africa’s oncology landscape.Early intervention is vital, and we must equip our patients with knowledge to recognize the signs. As part of our "Listen to Your Body" series, we are raising awareness about colorectal cancer—a disease that often starts silently but can have serious consequences if left undetected. Early detection through advanced technologies and streamlined workflows is vital for improving patient care. Empowering Patients Through Innovation To combat colorectal cancer effectively, we must integrate prevention and diagnosis with cutting-edge automation technologies. We can leverage automation in our practice through: Annual Reminders: Automated systems can send patients timely reminders for screenings, fostering proactive health management. Long-Term Data Tracking: Encourage the use of technology that enables tracking of patient history, which aids in personalized care and early detection. Streamlined Workflows: Implement innovative tools to enhance diagnostic accuracy and treatment processes, ultimately improving patient outcomes. Regular screening is your first line of defense. Use innovative technologies to improve diagnosis and streamline patient workflows. As oncology professionals, we play a crucial role in empowering our communities. Share this information with your patients to encourage regular screenings and awareness of early warning signs. Join the Movement! By promoting knowledge and leveraging automation, we can work together to reduce the impact of cancer in our communities. Let’s encourage our patients to listen to their bodies and take action for their health. #ColorectalCancer #CancerAwareness #OncologyProfessionals #PatientEmpowerment #AutomationInHealthcare

A successful example of when pharma and medical experts work together to gather insights from over 300 patients (and caregivers) to better understand the decision-making processes and knowledge levels of patients with Hepatobiliary Cancer. Uncovering the patient journey, and the experience of those around them, can enable better approaches to supporting patients to be identified, in line with real-world patient needs and preferences. It also helps understand and improve the experience for future patients and their caregivers. #behindpatienteyes #livercancer #hcc #btc #patientengagement #patientcare #patientjourney #patientexperience

Bone Metastases in #NSCLC: Symptoms, Treatment, and Hope #LungCancer #CancerAwareness Did you know that bone metastases are a common complication of non-small cell lung cancer (NSCLC)? While there's currently no cure, there are ways to manage symptoms and extend life expectancy. ✨ This article from Everyday Health explores: - How NSCLC spreads to bones - Signs and symptoms to watch for - Treatment options available, including medications, procedures, and palliative care 🩻 ♀️ - Importance of talking to your doctor and exploring clinical trials. https://lnkd.in/eHFvFG7h Early detection is key! If you have any concerns, don't hesitate to reach out to your healthcare provider. Let's all work together to raise awareness about lung cancer and empower patients with knowledge.

Exciting news! The first patients have been enrolled in LOOP! Pneumonitis/Interstitial Lung Disease (ILD), a serious and often difficult to detect side effect of multiple cancer treatments, can be devastating for certain patients while jeopardizing treatment outcomes for others. But today, we're taking a big step forward in advancing a digital solution to help patients and providers mitigate this risk. Our groundbreaking "LOOP" study has enrolled its first patients. This is a standard of care study to inform our understanding of the prodromal clinical manifestations of ILD and related patient and clinician behaviors in the clinical care setting. Link: https://lnkd.in/g6PKbpa3 Evidence like this may demonstrate clinical benefit and utility for an AI-powered patient and care provider digital solution to identify patients at a higher risk of ILD. It will also collect and track early signs of this low prevalence high morbidity side effect of over 44 oncology treatments. Such technology will provide data-driven and real-time quantification of individual risks during the course of treatment, enabling clinicians to deliver personalized toxicity monitoring and achieve better treatment outcomes. Our team is relentlessly focused on following the science, and we are thrilled to have the opportunity to collect potentially practice-changing, prospective, empirical evidence to inform the natural history and early detection ILD pneumonitis, and to ideally optimize its management. We are incredibly grateful to the LOOP patient participants and recognise their commitment. Let's continue this journey of making a positive impact on patients' lives and redefine cancer care. #DigitalTherapeutics #ClinicalInnovation #HealthcareTransformation #LungCancer Melissa MarvelElisabeth Piault-LouisJoseph HughesSolomon DhanduEmmette HutchisonDorian ZoumplisNiko AndreEthan Basch

Pembrolizumab (Keytruda) is revolutionizing cancer treatment through innovative immunotherapy. This groundbreaking therapy, with its significant efficacy in treating metastatic HER2-positive gastric and gastroesophageal junction adenocarcinomas, conditions associated with high mortality rates, offers a beacon of hope. Patients have experienced remarkable tumor response, improved symptoms, and enhanced quality of life. Key findings from the study include substantial tumor reduction, symptom relief, and prolonged progression-free survival, indicating effective disease control. Conducted with insights from 58 medical oncologists across Canada, Austria, and Belgium, the study utilized a quantitative approach involving in-depth interviews and follow-up imaging studies to confirm tumor responses. This comprehensive analysis highlights Pembrolizumab’s transformative potential, which lies in its ability to significantly improve patient outcomes and reduce mortality rates. It underscores its critical role in personalized medicine and immune checkpoint inhibition. Despite its success, challenges such as managing immune-related adverse events and overcoming resistance mechanisms remain. This underscores the importance of ongoing research and collaboration, a call to action for all of us to optimize Pembrolizumab’s use and improve patient outcomes globally. #CancerTreatment #Immunotherapy #Pembrolizumab #Keytruda #HER2Positive #Oncology #GastricCancer #GEJ #TumorReduction #SymptomRelief #QualityOfLife #ClinicalResearch #MedicalOncology #PatientCare #CancerInnovation #PersonalizedMedicine

Exciting News from the IMPORTANT Project! We are happy to announce the publication of our latest paper: "Clinical trials in older patients with cancer – typical challenges, possible solutions and a paradigm of study design in breast cancer". Why This Matters: With the prevalence of older breast cancer patients rapidly increasing, they remain significantly underrepresented in clinical trials. This publication addresses the barriers to recruitment of older patients and proposes innovative solutions to design optimal clinical trials, illustrated through the paradigm of the #IMPORTANTtrial. 🔬 Key Innovations: 1. Individualized Shared Decision-Making: Tailoring the initial dose of CDK 4/6-inhibitors based on frailty status to enhance patient outcomes. 2. Optimized Recruitment Methodology: Leveraging multidisciplinary collaboration to improve trial participation among older and less tech-savvy patients. 3. Financial Model Innovation: Developing a model to optimize healthcare costs, reduce financial toxicity and manage side-effect toxicity for older patients. 4. Geriatric Cancer Registry: Establishing a comprehensive registry to advance research and clinical practice in geriatric oncology. 📈 Impact: Our goal is to deliver high-level evidence (level I) that can transform current clinical practices and improve the quality of life for older breast cancer patients. The combination of CDK 4/6-inhibitors and endocrine therapy, supported by mandatory comprehensive geriatric assessments (CGAs), represents a significant step forward in personalized cancer care. We invite you to read the full publication to explore the detailed strategies and innovations that the #IMPORTANT project brings to the forefront of clinical research. Together, we can pave the way for more inclusive, effective and patient-centered cancer treatments. https://lnkd.in/dhe8TaQJ #ImportantEUProject #HorizonEU #EUResearch #ResearchCollaboration #ClinicalTrials #BreastCancerResearch #Health

What do your heart and cancer have in common? More than you may think. Cardio-oncology focuses on preventing and managing heart disease during cancer treatment. This field is a welcomed addition to personalized treatment regimens designed to limit cardiotoxicity. Learn more from nurse navigator Sharon Gentry. #cardiooncology #ConquerMag